AcelRx Pharmaceuticals In... (ACRX)
AcelRx Pharmaceuticals Statistics
Share Statistics
AcelRx Pharmaceuticals has 16.95M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 16.95M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 32 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1019.14 and the forward PE ratio is null. AcelRx Pharmaceuticals's PEG ratio is 10.19.
| PE Ratio | -1019.14 |
| Forward PE | n/a |
| PS Ratio | 16104.23 |
| Forward PS | n/a |
| PB Ratio | 743.27 |
| P/FCF Ratio | -595.94 |
| PEG Ratio | 10.19 |
Enterprise Valuation
AcelRx Pharmaceuticals has an Enterprise Value (EV) of 10.48B.
| EV / Sales | 16095.44 |
| EV / EBITDA | -620.41 |
| EV / EBIT | -599.02 |
| EV / FCF | -595.62 |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.
| Current Ratio | 2.56 |
| Quick Ratio | 2.56 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 126.04 |
Financial Efficiency
Return on Equity is -72.93% and Return on Invested Capital is -119.74%.
| Return on Equity | -72.93% |
| Return on Assets | -50.44% |
| Return on Invested Capital | -119.74% |
| Revenue Per Employee | $34,263.16 |
| Profits Per Employee | $-541,421.05 |
| Employee Count | 19 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -6.72% in the last 52 weeks. The beta is 0.52, so AcelRx Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.52 |
| 52-Week Price Change | -6.72% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 138,824 |
Income Statement
In the last 12 months, AcelRx Pharmaceuticals had revenue of 651K and earned -10.29M in profits. Earnings per share was 0.
| Revenue | 651K |
| Gross Profit | 651K |
| Operating Income | -16.89M |
| Net Income | -10.29M |
| EBITDA | -16.89M |
| EBIT | -10.42M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 5.72M in cash and 0 in debt, giving a net cash position of 5.72M.
| Cash & Cash Equivalents | 5.72M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -444.23M |
| Total Assets | 23.26M |
| Working Capital | 10.85M |
Cash Flow
In the last 12 months, operating cash flow was -17.49M and capital expenditures -100K, giving a free cash flow of -17.59M.
| Operating Cash Flow | -17.49M |
| Capital Expenditures | -100K |
| Free Cash Flow | -17.59M |
| FCF Per Share | 0 |
Margins
Gross margin is 100%, with operating and profit margins of -2594.32% and -1580.18%.
| Gross Margin | 100% |
| Operating Margin | -2594.32% |
| Pretax Margin | -1580.18% |
| Profit Margin | -1580.18% |
| EBITDA Margin | -2594.32% |
| EBIT Margin | -2594.32% |
| FCF Margin | -2702.3% |
Dividends & Yields
ACRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.1% |
| FCF Yield | -0.17% |
Analyst Forecast
Currently there are no analyst rating for ACRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 26, 2022. It was a backward split with a ratio of 1:20.
| Last Split Date | Oct 26, 2022 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -26.17 |
| Piotroski F-Score | 3 |